quinazolines has been researched along with bay 80-6946 in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (45.90) | 24.3611 |
| 2020's | 33 (54.10) | 2.80 |
| Authors | Studies |
|---|---|
| Bull, CO; Fracasso, PR; Haegebarth, A; Hentemann, M; Liu, N; Mumberg, D; Rowley, BR; Schatz, CA; Schneider, C; Scott, WJ; Wilhelm, SM; Wilkie, DP; Ziegelbauer, K | 1 |
| Baselga, J; Chandarlapaty, S; de Stanchina, E; Huang, X; Jiang, X; Liu, N; Monian, P; Qin, AC; Rodrik-Outmezguine, V; Rosen, N; Schneider, C; Toy, W; Will, M; Yao, Z | 1 |
| Emmert, S; Liu, N; Pletz, N; Schneider, P; Schön, M; Schön, MP; Seitz, CS; Zachmann, K; Ziegelbauer, K | 1 |
| Carr, A; Cremona, M; Elster, N; Eustace, AJ; Hennessy, BT; Morgan, C; O'Grady, A; Toomey, S | 1 |
| Baumann, M; Frenzel, LP; Göckeritz, E; Hallek, M; Kerwien, S; Klein, C; Krause, G; Landwehr, T; Liu, N; Neumann, L; Vondey, V; Wendtner, CM; Wigger, M | 1 |
| Brands, M; Bull, CO; Bullion, AM; Esler, W; Fracasso, RP; Garrison, T; Hamilton, M; Hentemann, MF; Jenkins, S; Johnson, J; Lefranc, J; Levy, J; Liu, N; Michels, M; Redman, A; Robbins, AH; Rowley, RB; Schaefer, M; Scott, WJ; Stasik, E; Wilkie, DP; Wood, JE; Xiao, H | 1 |
| Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T | 1 |
| Appleman, LJ; Beeram, M; Chadha, M; Chu, E; Ejadi, S; Fulk, M; Genvresse, I; Jeffers, M; Lotze, MT; Mountz, JM; Papadopoulos, KP; Patnaik, A; Peña, C; Ramanathan, RK; Rasco, DW; Reif, S; Sachdev, JC; Tolcher, AW; Toledo, FG; Weiss, GJ; Xia, C | 1 |
| Bando, H; Doi, T; Fuse, N; Kaneko, M; Kojima, T; Miyamoto, H; Ohtsu, A; Osada, M; Yoshino, T | 1 |
| Lim, SY; Menzies, AM; Rizos, H | 1 |
| Assouline, SE; Bouabdallah, K; Bron, D; Childs, BH; Cunningham, D; Dreyling, M; Garcia-Vargas, J; Giurescu, M; Gorbatchevsky, I; Hiemeyer, F; Koechert, K; Linton, K; Liu, L; Morschhauser, F; Neves, M; Peña, C; Thieblemont, C; Verhoef, G; Vitolo, U; Zinzani, PL | 1 |
| Genvresse, I; Gerisch, M; Granvil, C; Lang, D; Reif, S; Reschke, S; Rohde, G; Schwarz, T; van der Mey, D | 1 |
| Bouabdallah, K; Childs, BH; Cupit, L; Demeter, J; Dreyling, M; Follows, GA; Garcia-Vargas, J; Giurescu, M; Hiemeyer, F; Kim, WS; Köchert, K; Kosinova, M; Lenz, G; Leppä, S; Liu, L; Mollica, L; Morschhauser, F; Nagler, A; Özcan, M; Panayiotidis, P; Peña, C; Santoro, A; Seidel, H; Stevens, DA; Trevarthen, D; Yin, S; Zinzani, PL | 1 |
| Das, M | 1 |
| Markham, A | 1 |
| Thieblemont, C | 1 |
| Ajavon-Hartmann, A; Alberts, SR; Genvresse, I; Grilley-Olson, JE; Kelly, A; Kim, RD; Peña, C; Xia, C | 1 |
| Janku, F; Meric-Bernstam, F; Yap, TA | 1 |
| Dreyling, M | 1 |
| Hallek, M; Hassenrück, F; Krause, G | 1 |
| Bojarczuk, K; Chapuy, B; Chen, L; Lawton, LN; Letai, A; Mandato, E; Ryan, JA; Shipp, MA; Stachura, J; Villalobos-Ortiz, M; Wienand, K | 1 |
| Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Dittakavi, S; Mullangi, R | 1 |
| Cheson, BD; Dreyling, M; Ewer, MS; Farooki, A; Fisher, RI; Goncalves, MD; Lenz, G; O'Brien, S; Yu, A; Zinzani, PL | 1 |
| Eltantawy, A; Evans, K; Sebea, E; Vallejos, X | 1 |
| Kim, JH; Kim, WS; Park, C | 1 |
| Arkenau, HT; Awada, A; Cisternas, G; Cunningham, D; Fruchart, C; Genvresse, I; Granvil, C; Grevel, J; Kneip, C; Köchert, K; Liu, L; Machiels, JP; Morschhauser, F; Peña, CE; Peyrade, F; Reschke, S; Rottey, S; Rule, SAJ; Salles, G; Shen, K; Zhang, J | 1 |
| Bouabdallah, K; Childs, BH; Demeter, J; Dimou, M; Dreyling, M; Follows, G; Garcia-Vargas, J; Hiemeyer, F; Kim, WS; Kosinova, M; Lenz, G; Leppä, S; Miriyala, A; Mollica, L; Morschhauser, F; Munoz, J; Nagler, A; Özcan, M; Rodrigues, L; Santoro, A; Stevens, DA; Trevarthen, D; Zinzani, PL | 1 |
| Booth, L; Dent, P; Hancock, JF; Hoff, DV; Poklepovic, A | 1 |
| Ardeshna, K; Beckmann, G; Buvaylo, V; Childs, BH; Chong, G; Gorbatchevsky, I; Haaber, J; Haioun, C; Hawkes, E; Hiemeyer, F; Lenz, G; Lippert, S; Peña, C; Piraino, P; Salles, G; Seog Heo, D; Shi, W; Thye Lim, S; Verhoef, G | 1 |
| Arribas, AJ; Berthold, M; Bertoni, F; Cascione, L; Gaudio, E; Gritti, G; Jourdan, T; Kwee, I; Lange, M; Liu, N; Margheriti, F; Politz, O; Rinaldi, A; Rossi, D; Scalise, L; Sperl, C; Spriano, F; Stathis, A; Sturz, A; Tarantelli, C; Zucca, E | 1 |
| Anghore, D; Bhatia, R; Chawla, P; Kumar, A; Rawal, RK; Saini, V | 1 |
| Camilo Barreto, J; Ejadi, S; Fang, B; Gao, L; Kannan, A; Nguyen, QH; Yamamoto, M; Zhao, H; Zhao, S | 1 |
| Carlo-Stella, C; Magagnoli, M; Santoro, A | 1 |
| Cheson, BD; Narkhede, M | 1 |
| Dittakavi, S; Kumar, R; Mullangi, R; Siddesh, A; Sriram, D; Trivedi, RK; Zainuddin, M; Zakkula, A | 1 |
| Tian, H; Yan, J; Yang, S; Zhang, Y; Zhao, H | 1 |
| Al-Toubah, TE; Cao, B; Centeno, BA; Kim, J; Kim, RD; Mehta, R; Tan, ES | 1 |
| Kim, JS; Kim, SJ; Kim, T; Kim, WS; Koh, Y; Moon, JH; Park, GS; Park, J; Shin, HJ; Yang, DH; Yhim, HY | 1 |
| Childs, BH; Dreyling, M; Follows, GA; Garcia-Vargas, J; Hiemeyer, F; Mollica, L; Nagler, A; Özcan, M; Panayiotidis, P; Santoro, A; Stevens, D; Trevarthen, D; Zinzani, PL | 1 |
| Chen, Y; Deng, H; Du, W; Gao, H; He, Q; Lan, T; Li, T; Liu, Y; Meng, X; Rao, Y; Shao, X; Sun, X; Tao, X; Tong, Y; Wang, L; Wang, W; Wu, Y; Xu, A; Yang, B; Ying, M; Zhong, T | 1 |
| Follows, GA; Munoz, J; Nastoupil, LJ | 1 |
| Baker, R; Bondarenko, I; Bouabdallah, K; Cao, A; Capra, M; Childs, BH; Feng, J; Galiulin, R; Geissler, K; Hamed, A; Hiemeyer, F; Jin, J; Jurczak, W; Lazaroiu, M; Li, W; Lin, T; Lv, F; Matasar, MJ; Mehra, A; Özcan, M; Sapunarova, K; Saydam, G; Shi, Y; Soler, LM; Szomor, Á; Uchida, T; Wang, MC; Yañez, E; Zhang, Q; Zinzani, PL | 1 |
| Killock, D | 1 |
| Abramson, VG; Ayers, GD; Chen, SC; Mayer, IA; Richmond, A; Saleh, N; Yan, C; Yang, J | 1 |
| Barth, TFE; Buske, C; Dreyhaupt, J; Grunenberg, A; Kaiser, LM; Kiesewetter, B; Möller, P; Muche, R; Raderer, M; Schmelzle, B; Viardot, A; Woelfle, S | 1 |
| Asgari, Z; Da Silva Ferreira, M; de Stanchina, E; Denis, L; Gupta, S; Knezevic, A; Portelinha, A; Reddy, S; Seshan, V; Smith, RA; Thompson, S; Younes, A | 1 |
| Buvaylo, V; Childs, BH; Dreyling, M; Fletcher, M; Leppä, S; Matasar, MJ; Pedersen, M; Santoro, A; Zinzani, PL | 1 |
| Kang, W; Kwon, JY; Lee, C; Lee, H; Maher, L; Michaud, M; Ning, G; Silva, M; Suh, YS; Zhang, C; Zhu, Q | 1 |
| Brainson, CF; Byrd, AL; Chen, F; DuCote, TJ; Liu, J; Song, X; Wang, C | 1 |
| Hasegawa, J; Hikita, T; Kugii, Y; Morioka, S; Nakanishi, H; Oneyama, C; Sakihara, T; Sasaki, J; Sasaki, T; Suzuki, A; Tokuda, E; Yamamoto, T; Yamazaki, M | 1 |
| Arteaga, CL; Chen, AP; Conley, BA; Damodaran, S; Deming, DA; Flaherty, KT; Gray, RJ; Hamilton, SR; Harris, LN; McShane, LM; Mitchell, EP; O'Dwyer, PJ; Patton, DR; Rubinstein, LV; Suga, JM; Wang, V; Williams, PM; Wright, JJ; Zhao, F | 1 |
| Adib, D; Gupta, D; Mamlouk, K; Nellesen, D; Proudman, D; Yang, J | 1 |
| Batlevi, C; Biggar, E; Espeleta, JA; Kumar, A; Lam, HY; Matasar, M; Nichols, C; Owens, C; Qiu, A; Qualls, D; Salles, G; Seshan, V; Subzwari, S; Whiting, K; Younes, A | 1 |
| Childs, BH; Cisternas, G; Du, T; Garcia-Vargas, J; Huang, F; Liu, W; Mehra, A; Niu, Y; Ping, L; Reschke, S; Song, Y; Sun, Y; Wang, X; Xie, Y; Zhu, J | 1 |
| Bestha, RM; Dittakavi, S; Kiran, V; Manju, SVN; Mullangi, R; Tripathy, HK | 1 |
| Childs, BH; Fukuhara, N; Garcia-Vargas, J; Hatake, K; Iriyama, C; Kamezaki, K; Kuroda, J; Kusumoto, S; Makita, S; Maruyama, D; Masuda, S; Minami, H; Nagai, H; Suehiro, Y; Terao, Y; Tobinai, K; Tsujino, T; Tsukamoto, N; Uchida, T; Yanada, M; Yasuda, M | 1 |
| Anders Kolb, E; Earley, E; Erickson, S; Gatto, G; Gill, J; Gorlick, R; Harrison, D; Hingorani, P; Houghton, P; Kurmasheva, R; Roth, M; Smith, M; Teicher, B; Zhang, W | 1 |
| Austin, R; Beckert, V; Childs, BH; Garmann, D; Hiemeyer, F; Mongay Soler, L; Morcos, PN; Moss, J; Zinzani, PL | 1 |
11 review(s) available for quinazolines and bay 80-6946
| Article | Year |
|---|---|
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
Copanlisib: First Global Approval.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; Drug Approval; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines; Rituximab; United States; United States Food and Drug Administration | 2017 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
Targeting the PI3K pathway in cancer: are we making headway?
Topics: Class I Phosphatidylinositol 3-Kinases; Everolimus; Humans; Molecular Targeted Therapy; Neoplasms; Oncogene Protein v-akt; Purines; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Topics: Animals; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones | 2018 |
Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Topics: Administration, Intravenous; Aged; Angiogenesis Inhibitors; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence | 2019 |
Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Lymphoma; Molecular Structure; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2020 |
Copanlisib for the treatment of adults with relapsed follicular lymphoma.
Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Humans; Lymphoma, Follicular; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence | 2020 |
Copanlisib in the treatment of non-Hodgkin lymphoma.
Topics: Biomarkers; Clinical Trials as Topic; Disease Management; Disease Susceptibility; Humans; Hyperglycemia; Hypertension; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Pyrimidines; Quinazolines; Signal Transduction; Treatment Outcome | 2020 |
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Topics: Humans; Lymphoma; Pyrimidines; Quinazolines | 2021 |
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-
Topics: Benzamides; Biphenyl Compounds; Child, Preschool; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Lymphoma, Follicular; Morpholines; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Purines; Pyridones; Pyrimidines; Quinazolines; Quinazolinones; Risk | 2022 |
17 trial(s) available for quinazolines and bay 80-6946
| Article | Year |
|---|---|
Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Intravenous; Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Quinazolines | 2016 |
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Topics: Aged; Antineoplastic Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Humans; Lymphoma; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Recurrence; Survival Analysis | 2017 |
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Isoenzymes; Lymphoma, B-Cell; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Transcriptome | 2017 |
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Treatment Outcome | 2018 |
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Topics: Biopsy; Cell Line, Tumor; Female; Humans; Lymphoma; Male; Neoplasms; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines | 2020 |
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; CD79 Antigens; Female; High-Throughput Nucleotide Sequencing; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence | 2020 |
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Progression-Free Survival; PTEN Phosphohydrolase; Pyrimidines; Quinazolines | 2021 |
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Pyrimidines; Quinazolines; Treatment Outcome | 2021 |
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Rituximab | 2021 |
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, B-Cell, Marginal Zone; Phosphoinositide-3 Kinase Inhibitors; Prospective Studies; Pyrimidines; Quinazolines | 2021 |
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Feasibility Studies; Female; Humans; Immunotherapy; Lymphoma, B-Cell; Male; Middle Aged; Pyrimidines; Quinazolines; Rituximab | 2021 |
Phase II Study of Copanlisib in Patients With Tumors With
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines | 2022 |
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrimidines; Quinazolines | 2022 |
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Topics: China; Humans; Lymphoma, Non-Hodgkin; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines | 2022 |
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
Topics: Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quinazolines | 2023 |
33 other study(ies) available for quinazolines and bay 80-6946
| Article | Year |
|---|---|
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Topics: Administration, Intravenous; Animals; Apoptosis; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Nude; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.
Topics: Apoptosis; Cell Line, Tumor; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Signaling System; MCF-7 Cells; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2014 |
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Humans; In Vitro Techniques; Melanoma; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Xenograft Model Antitumor Assays | 2014 |
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Lapatinib; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab | 2015 |
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Isoenzymes; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones; Rituximab; Signal Transduction | 2015 |
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Class Ib Phosphatidylinositol 3-Kinase; Drug Discovery; Humans; Hydrogen Bonding; Imidazoles; Molecular Docking Simulation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2016 |
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines | 2016 |
Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [
Topics: Administration, Intravenous; Class I Phosphatidylinositol 3-Kinases; Healthy Volunteers; Humans; Male; Middle Aged; Pyrimidines; Quinazolines | 2017 |
Copanlisib in heavily pretreated indolent lymphoma.
Topics: Humans; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines | 2017 |
Copanlisib (Aliqopa) for relapsed follicular lymphoma.
Topics: Antineoplastic Agents; Drug Costs; Drug Interactions; Humans; Lymphoma, Follicular; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Signal Transduction; Treatment Outcome | 2018 |
A closer look at copanlisib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Clinical Trials as Topic; Disease Management; Humans; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Treatment Outcome | 2018 |
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Oligopeptides; Phosphoinositide-3 Kinase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Stromal Cells | 2019 |
LC-ESI-MS/MS determination of copanlisib, a novel PI3K inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice.
Topics: Animals; Chromatography, Liquid; Linear Models; Male; Mice; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines | 2019 |
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Topics: Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Humans; Interleukin-6; Isoquinolines; Janus Kinase Inhibitors; Lymphoma, B-Cell; Lymphoma, T-Cell; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; STAT3 Transcription Factor; STAT5 Transcription Factor; Transfection; Tumor Suppressor Proteins | 2019 |
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Hypertension; Lymphoma, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Pyrimidines; Quinazolines; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2020 |
Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Topics: Cell Line, Tumor; Cell Survival; Humans; MAP Kinase Signaling System; Models, Biological; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Valproic Acid | 2020 |
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2020 |
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Topics: Animals; Apoptosis; Carcinoma, Merkel Cell; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Isoforms; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2020 |
Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Isoquinolines; Linear Models; Liquid-Liquid Extraction; Male; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity | 2021 |
Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Topics: Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines | 2021 |
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
Topics: Antineoplastic Agents; Aurora Kinase A; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Discovery; Gene Expression Regulation, Leukemic; Humans; Ikaros Transcription Factor; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Myeloid Progenitor Cells; Piperazines; Primary Cell Culture; Proteolysis; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Structure-Activity Relationship; Transcriptome; Triazoles | 2021 |
Copanlisib safe and active in combination.
Topics: Humans; Pyrimidines; Quinazolines | 2021 |
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Granulocytes; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Inhibitory Concentration 50; Mice, Nude; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; raf Kinases; ras Proteins; Xenograft Model Antitumor Assays | 2021 |
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidines; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
Topics: Animals; Antineoplastic Agents; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Humans; Lung Neoplasms; Mice; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2022 |
A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their disease-associated regulation.
Topics: Animals; Chromatography, Affinity; Class I Phosphatidylinositol 3-Kinases; Epidermal Growth Factor; Exosomes; Gene Expression; HEK293 Cells; HeLa Cells; Humans; Male; Mass Spectrometry; Metabolome; Mice; PC-3 Cells; Phosphatidylinositols; Prostate; Prostatic Neoplasms; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Stereoisomerism | 2022 |
Validated liquid chromatography-tandem mass spectrometry method for simultaneous quantitation of bendamustine and copanlisib in mouse plasma: Application to a pharmacokinetic study in mice.
Topics: Animals; Bendamustine Hydrochloride; Chromatography, High Pressure Liquid; Chromatography, Liquid; Mice; Pyrimidines; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2022 |
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma.
Topics: Child; Humans; Osteosarcoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines | 2023 |
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines; Rituximab | 2023 |